• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拉丁美洲周围血管介入注册研究的基本原理与设计:来自SOLACI周围血管介入研究的见解

Rationale and Design of the Latin-American Registry of Peripheral Interventions: Insights From SOLACI Peripheral.

作者信息

Virgen-Carrillo Luis R, Díaz-Sandoval Larry, Rossi Maximiliano, Pedernera Gustavo O, Duarte Ernesto R, Pascua Julio A, Lugo-Gavidia Leslie M, Lamelas Pablo

机构信息

Department of Interventional Cardiology, Virgen Cardiovascular Research, Guadalajara, Mexico.

Department of Interventional Cardiology, Universidad Autonóma de Guadalajara, Guadalajara, Mexico.

出版信息

J Soc Cardiovasc Angiogr Interv. 2024 Apr 4;3(7):101931. doi: 10.1016/j.jscai.2024.101931. eCollection 2024 Jul.

DOI:10.1016/j.jscai.2024.101931
PMID:39132002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11307582/
Abstract

BACKGROUND

Chronic limb-threatening ischemia (CLTI) represents the most advanced stage of lower extremity peripheral artery disease (PAD). The aim of this manuscript is to provide an overview of the demographic and clinical characteristics of patients with lower-limb peripheral artery disease, as well as the procedural and technical aspects of peripheral endovascular interventions in Latin-America.

METHODS

The SOLACI peripheral registry is a prospective, multi-center, observational, and hospital-based registry of patients with lower-limb PAD, who are treated with endovascular interventions across Latin American countries.

RESULTS

A total of 1057 independent procedures (997 patients) were analyzed in this report. The most common clinical presentation was CLTI (61.2%): Advanced stage of the disease was common, and the symptomatic classification was predominately Rutherford V (minor tissue loss) in 37.6%. Index endovascular procedures mainly treated femoral-popliteal and infrapopliteal regions. Disease extending across multiple vascular territories was common and 27.6% of patients underwent angioplasty of multiple regions during the same procedure. There was a high prevalence of cardiovascular risk factors and concomitant comorbidities: hypertension (84.5%), dyslipidemia 67.4%), diabetes mellitus (64.7%), myocardial infarction (17%) and stroke (8.4%). Major adverse events during hospitalization included death from any cause (1.3%), cardiovascular death (0.7 %), myocardial infarction (0.4%), stroke (0.1%) and bleeding (0.8%).

CONCLUSIONS

Real-world data on lower limb-PAD in Latin American countries will help us identify unmet needs and generate evidence-based recommendations to facilitate the development of more effective preventive and treatment strategies according to each country's necessities and resources.

摘要

背景

慢性肢体威胁性缺血(CLTI)是下肢外周动脉疾病(PAD)的最严重阶段。本文旨在概述下肢外周动脉疾病患者的人口统计学和临床特征,以及拉丁美洲外周血管腔内介入治疗的操作和技术方面。

方法

SOLACI外周登记系统是一个前瞻性、多中心、观察性且基于医院的登记系统,登记的是拉丁美洲国家接受血管腔内介入治疗的下肢PAD患者。

结果

本报告共分析了1057例独立手术(997例患者)。最常见的临床表现是CLTI(61.2%):疾病晚期很常见,症状分类主要为卢瑟福V级(轻度组织缺损),占37.6%。首次血管腔内手术主要治疗股腘动脉和腘以下区域。疾病累及多个血管区域很常见,27.6%的患者在同一次手术中接受了多个区域的血管成形术。心血管危险因素和合并症的患病率很高:高血压(84.5%)、血脂异常(67.4%)、糖尿病(64.7%)、心肌梗死(17%)和中风(8.4%)。住院期间的主要不良事件包括任何原因导致的死亡(1.3%)、心血管死亡(0.7%)、心肌梗死(0.4%)、中风(0.1%)和出血(0.8%)。

结论

拉丁美洲国家下肢PAD的真实世界数据将有助于我们识别未满足的需求,并生成基于证据的建议,以便根据每个国家的需求和资源制定更有效的预防和治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54dd/11307582/59e44982caf3/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54dd/11307582/5526e24a3c28/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54dd/11307582/465b479909a5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54dd/11307582/59e44982caf3/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54dd/11307582/5526e24a3c28/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54dd/11307582/465b479909a5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54dd/11307582/59e44982caf3/gr3.jpg

相似文献

1
Rationale and Design of the Latin-American Registry of Peripheral Interventions: Insights From SOLACI Peripheral.拉丁美洲周围血管介入注册研究的基本原理与设计:来自SOLACI周围血管介入研究的见解
J Soc Cardiovasc Angiogr Interv. 2024 Apr 4;3(7):101931. doi: 10.1016/j.jscai.2024.101931. eCollection 2024 Jul.
2
Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.下肢外周动脉疾病的支架置入术:一项基于证据的分析。
Ont Health Technol Assess Ser. 2010;10(18):1-88. Epub 2010 Sep 1.
3
The Dutch chronic lower limb-threatening ischemia registry (THRILLER): A study protocol for popliteal and infrapopliteal endovascular interventions.荷兰慢性下肢缺血威胁性登记研究(THRILLER):腘动脉和腘下动脉腔内介入治疗的研究方案。
PLoS One. 2023 Jul 20;18(7):e0288912. doi: 10.1371/journal.pone.0288912. eCollection 2023.
4
Demographic and procedural characteristics in the RECording COurses of vasculaR Diseases (RECCORD) registry - the first 1000 patients.血管疾病记录病程(RECCORD)登记研究中的人口统计学和手术特征——首批1000例患者
Vasa. 2020 Aug;49(5):382-388. doi: 10.1024/0301-1526/a000882. Epub 2020 Jul 1.
5
Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study.利伐沙班用于下肢外周动脉疾病血运重建术后有症状患者的双抗血栓和抗血小板治疗比较:一项回顾性队列研究
Ther Adv Chronic Dis. 2023 Dec 6;14:20406223231213262. doi: 10.1177/20406223231213262. eCollection 2023.
6
Aorto-iliac and infrainguinal artery occlusive disease: different revascularization options according to the critical limb threatening ischemia category.主髂动脉及下肢动脉阻塞性疾病:根据严重肢体缺血威胁类别选择不同的血运重建方法。
Int Angiol. 2023 Jun;42(3):209-215. doi: 10.23736/S0392-9590.23.04992-1. Epub 2023 Apr 17.
7
Three-Year Outcomes of Orbital Atherectomy for the Endovascular Treatment of Infrainguinal Claudication or Chronic Limb-Threatening Ischemia.用于血管腔内治疗股腘动脉闭塞症或慢性肢体威胁性缺血的眼眶斑块旋切术的三年疗效
J Endovasc Ther. 2020 Oct;27(5):714-725. doi: 10.1177/1526602820935611. Epub 2020 Jul 3.
8
Clinical outcomes of bypass-first versus endovascular-first strategy in patients with chronic limb-threatening ischemia due to infrageniculate arterial disease.对于因膝下动脉疾病导致慢性肢体威胁性缺血的患者,采用旁路优先与血管内优先策略的临床结果。
J Vasc Surg. 2019 Jan;69(1):156-163.e1. doi: 10.1016/j.jvs.2018.05.244.
9
Characteristics and Outcomes of Patients With Diabetes Mellitus Undergoing Peripheral Vascular Intervention for Infrainguinal Symptomatic Peripheral Artery Disease.糖尿病患者下肢症状性外周动脉疾病行外周血管介入治疗的特征和结局。
Vasc Endovascular Surg. 2021 Feb;55(2):124-134. doi: 10.1177/1538574420968671. Epub 2020 Oct 23.
10
Rates of Intervention for Claudication versus Chronic Limb-Threatening Ischemia in Canada and United States.加拿大和美国的间歇性跛行与慢性肢体威胁性缺血的干预率。
Ann Vasc Surg. 2022 May;82:131-143. doi: 10.1016/j.avsg.2021.10.068. Epub 2021 Dec 10.

本文引用的文献

1
Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease.药物洗脱可吸收支架与血管成形术治疗下肢动脉疾病。
N Engl J Med. 2024 Jan 4;390(1):9-19. doi: 10.1056/NEJMoa2305637. Epub 2023 Oct 25.
2
A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.对于需要进行 below-the-knee(小腿)、伴或不伴额外更近端 below-inguinal(腹股沟下)血运重建以恢复肢体灌注的慢性肢体威胁性缺血患者,静脉旁路优先与最佳血管内治疗优先再血管化策略的比较(BASIL-2):一项开放标签、随机、多中心、3 期试验。
Lancet. 2023 May 27;401(10390):1798-1809. doi: 10.1016/S0140-6736(23)00462-2. Epub 2023 Apr 25.
3
Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia.慢性肢体威胁性缺血的手术或血管内治疗。
N Engl J Med. 2022 Dec 22;387(25):2305-2316. doi: 10.1056/NEJMoa2207899. Epub 2022 Nov 7.
4
Cardiovascular and Limb Events Following Endovascular Revascularization Among Patients ≥65 Years Old: An American College of Cardiology PVI Registry Analysis.65岁及以上患者血管内血运重建后的心血管和肢体事件:美国心脏病学会经皮血管内二尖瓣球囊成形术注册研究分析
J Am Heart Assoc. 2022 Jun 20;11(12):e024279. doi: 10.1161/JAHA.121.024279.
5
World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial.全球外周动脉疾病患者结局的地域差异:EUCLID 试验的见解。
Vasc Med. 2022 Feb;27(1):21-29. doi: 10.1177/1358863X211038620. Epub 2021 Sep 13.
6
Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.接受血管重建手术的外周动脉疾病患者中利伐沙班和阿司匹林的疗效:来自 VOYAGER PAD 试验的见解。
Circulation. 2021 Oct 5;144(14):1104-1116. doi: 10.1161/CIRCULATIONAHA.121.054835. Epub 2021 Aug 12.
7
Advances in Revascularization for Peripheral Artery Disease: Revascularization in PAD.外周动脉疾病血运重建的进展:PAD 中的血运重建。
Circ Res. 2021 Jun 11;128(12):1885-1912. doi: 10.1161/CIRCRESAHA.121.318261. Epub 2021 Jun 10.
8
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.利伐沙班和阿司匹林在下肢外周动脉疾病血管重建中的应用:氯吡格雷对疗效和安全性的影响。
Circulation. 2020 Dec 8;142(23):2219-2230. doi: 10.1161/CIRCULATIONAHA.120.050465. Epub 2020 Nov 3.
9
The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease.COMPASS 试验:与阿司匹林相比,低剂量利伐沙班联合阿司匹林用于慢性血管疾病患者的净临床获益。
Circulation. 2020 Jul 7;142(1):40-48. doi: 10.1161/CIRCULATIONAHA.120.046048. Epub 2020 May 21.
10
Rivaroxaban in Peripheral Artery Disease after Revascularization.利伐沙班治疗血管重建术后外周动脉疾病
N Engl J Med. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052. Epub 2020 Mar 28.